Shannon Stott's Biography

Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

The Stott laboratory is comprised of bioengineers and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, we are interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, we have developed a microfluidic device that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. We are striving to employ new imaging modalities to extract as much information as possible from these rare cells while pushing the technology further for early cancer detection. Ultimately, we hope that by working in close partnership with the molecular and cell biologist at the Mass General Cancer Center, we can create new tools that directly impact patient care.

Microfluidic Liquid Biopsy: Isolation of Exosomes and Circulating Tumor Cells from Cancer Patients

Tuesday, 22 March 2016 at 12:00

Add to Calendar ▼2016-03-22 12:00:002016-03-22 13:00:00Europe/LondonMicrofluidic Liquid Biopsy: Isolation of Exosomes and Circulating Tumor Cells from Cancer PatientsSELECTBIOenquiries@selectbiosciences.com

Aggressive tumors will invade surrounding tissue due to rapidly dividing cancer cells that are nourished by an ample blood supply. As these cancer cells are multiplying, they release thousands of tiny particles into the blood stream, referred to as exosomes, which contain genetic information about the tumor. Whole cancer cells are also released from the tumor and these rare circulating tumor cells (CTCs) provide genetic and functional information about the patient’s cancer. Through a collaborative effort between bioengineers, biologists, and clinicians, our group at MGH has developed microfluidic devices to isolate both of these rare circulating biomarkers from whole blood. Data from these devices will be presented with a focus on our recent effort to characterize exosomes and CTCs from patients with glioblastoma. Through the microfluidic isolation of blood based biomarkers from glioblastoma patients, our goal is to obtain complementary data to the current standard of care radiologic measurements to help better guide treatment for this deadly cancer.

Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonExosomes and Microvesicles: Research, Biomarker Cargo and Therapeutic PotentialSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors